image
Mobile_image
eyebrow
For adults with previously untreated Stage 3 or 4 classical Hodgkin lymphoma
headline

How may I benefit from ADCETRIS?

section-tab-header
true
section-tab-text-wrap
true
collection-color-theme
color-theme-4-core-tinted-on-white
headline

ECHELON-1 study design

content

ECHELON-1 was a large, international clinical study of 1334 people that compared the effectiveness and safety of ADCETRIS plus AVD with ABVD chemotherapy in patients with previously untreated Stage 3 and 4 classical Hodgkin lymphoma.

  • 664 people were assigned to receive ADCETRIS plus AVD chemotherapy every 2 weeks for up to 12 doses
  • 670 people were assigned to receive ABVD chemotherapy every 2 weeks for up to 6 cycles


Researchers reviewed the modified progression-free survival results (primary endpoint) at approximately 2 years and the overall survival results (secondary endpoint) at around 6 years.

headline

Overall survival results

headline2

At 6 years of follow up, the overall survival results for patients treated with ADCETRIS plus AVD were significantly higher than those treated with ABVD chemotherapy alone.

image
Mobile_image
content
After 6 years of follow up, it was estimated that about 94% of the 664 people treated with ADCETRIS plus AVD were still alive compared with 89% of the 670 people treated with ABVD chemotherapy alone.

Median overall survival was not reached, because more than half of patients in either treatment group were still alive.
headline

Modified progression-free survival

headline2

At 2 years of follow up, the modified progression-free survival for patients treated with ADCETRIS plus AVD was higher than those treated with ABVD chemotherapy alone.

image
Mobile_image
content
After 2 years, about 82% of the 664 people treated with ADCETRIS plus AVD did not have their cancer grow or spread, need additional anticancer therapy, or die compared to about 77% of the 670 treated with traditional ABVD chemotherapy.

No significant difference in overall survival was observed at 2 years.
section-tabbed-title
Study Results
section-tab-header-alignment
center
headline

What safety information should I know about ADCETRIS?

icon
headline

The most important serious safety information

content
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML): Patients treated with ADCETRIS can have a rare, serious brain infection called PML that can lead to death. Tell your doctor immediately if you have mood or behavior changes, confusion, problems in thinking or loss of memory, changes in vision, speech, or walking, or decreased strength or weakness on one side of the body. PML may also be caused by prior treatments or diseases that weakened your immune system.

Do not take ADCETRIS with bleomycin because of possible serious side effects to the lungs. These are not the only side effects of ADCETRIS. Always tell your doctor about any side effects you experience.
icon
headline

Most common side effects while taking ADCETRIS plus AVD

content

In people treated with ADCETRIS plus AVD, the most common side effects that occurred in ≥20% of study patients were low red blood cell count (98%), low white blood cell count (91%), nerve damage (peripheral sensory neuropathy; PN) (65%), constipation (42%), vomiting (33%), diarrhea (27%), fever (27%), weight loss (22%), stomach pain (21%), and sores or swelling in the mouth (21%).


The most common serious side effects were significantly low numbers of white blood cells with a fever (17%), fever (7%), low numbers of white blood cells (3%), and pneumonia (3%).


For more information on side effects, please see the Important Safety Information at the bottom of this page and read the Important Facts about ADCETRIS, including BOXED WARNING.

collection-container
content-container
collection-container-variant
grid
collection-item-type
core-content , core-text
section-tabbed-title
Side Effects
section-tab-header-alignment
center
headline

Tell your doctor about any side effect concerns you have

content

Your doctor should prescribe granulocyte colony-stimulating factor (G-CSF) along with your ADCETRIS treatment right at the start. G-CSF is a medication that may help reduce the chance of neutropenia (low white blood cell count).


Don’t stop, change, or delay your ADCETRIS plus AVD treatment unless directed by your doctor. Your doctor may take additional steps to help manage side effects, including:

  • Reducing your ADCETRIS dosage, or delaying your next dose, until symptoms improve
  • Stopping ADCETRIS completely if side effects are severe or do not improve


For more information about understanding side effects, download a copy of the ADCETRIS side effects guide

collection-container
testimonial
collection-container-variant
small-image
collection-item-type
core-quote, core-text
headline

Amina’s treatment journey

content
Amina knew something was wrong and spoke up. Listening to herself and her body is what helped Amina find out she had Stage 3 classical Hodgkin lymphoma. Throughout this challenging diagnosis, she found support and encouragement from her family, friends, and healthcare team.
buttons
View Amina’s Story
disclaimer
Amina was compensated for sharing her story.

ADCETRIS will not work for everyone.
quote
When ADCETRIS was given with a chemotherapy called AVD, it showed a higher overall survival rate versus ABVD chemotherapy alone at 6 years. Those results mattered to me.
patient_name
Amina,
patient_description
Treated with ADCETRIS plus AVD
collection-container
card-grid-container
collection-item-type
core-card, core-text
collection-container-variant
grid-2
card_identifier
heading

Treatment Decision Guide

body
For additional 6-year follow-up data, review the Treatment Decision Guide, which can help you feel confident discussing options with your doctor.
cta
View the treatment decision guide
card_identifier
heading

Learn more about what you can expect before starting ADCETRIS treatment.

cta
How ADCETRIS is given
headline

Glossary

content

ABVD: A combination of 4 chemotherapies—Adriamycin, bleomycin, vinblastine, and dacarbazine.

AVD: A combination of 3 chemotherapies—Adriamycin, vinblastine, and dacarbazine.

G-CSF: Granulocyte colony-stimulating factor, a medication that can help boost white blood cell count.

Median: The middle number in a list of numbers.

Modified progression-free survival: The length of time during and after treatment a patient lives without cancer progression, death, or receiving another cancer treatment.

Neutropenia: Having low levels of a type of white blood cell called neutrophils that help your immune system. You could have a higher chance of getting an infection.

Overall survival: The length of time that patients remain alive after enrolling in a study.

Peripheral neuropathy: Nerve damage that can cause numbness or tingling in the hands or feet (sensory) and/or weakness in the arms or legs (motor).